TMCITREACE MEDICAL CONCEPTS, INC.
- GlobeNewswire
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical ...
- PR Newswire
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Treace Medical Concepts, Inc. (NASDAQ:... ...
- GlobeNewswire
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
PONTE VEDRA, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical ...
- Analyst Upgrades
Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $4
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts with a Hold and raises the price target from $2 to $4. ...
- GlobeNewswire
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
PONTE VEDRA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- AccessWire
Sidoti Events, LLC's June Small-Cap Virtual Conference
NEW YORK, NY / ACCESS Newswire / June 16, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Virtual Investor Conference ...
- GlobeNewswire
Treace to Present at the Sidoti Small Cap Conference
PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- GlobeNewswire
Treace Medical Concepts Reports First Quarter 2026 Financial Results
PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical ...
- GlobeNewswire
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- GlobeNewswire
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
PONTE VEDRA, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- Analyst Upgrades
Lake Street Maintains Buy on Treace Medical Concepts, Lowers Price Target to $7
Lake Street analyst Ben Haynor maintains Treace Medical Concepts with a Buy and lowers the price target from $7.5 to $7. ...
- GlobeNewswire
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical ...
- GlobeNewswire
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference
PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- GlobeNewswire
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026
PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- GlobeNewswire
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- GlobeNewswire
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology
PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- Analyst Upgrades
Stifel Maintains Hold on Treace Medical Concepts, Lowers Price Target to $3
Stifel analyst Rick Wise maintains Treace Medical Concepts with a Hold and lowers the price target from $5 to $3. ...
- GlobeNewswire
Treace to Present at 44th Annual J.P. Morgan Healthcare Conference
PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- Analyst Upgrades
Truist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $3
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts with a Hold and lowers the price target from $4 to $3. ...
- GlobeNewswire
Treace Medical Secures Up to $175 Million in Debt Financing
PONTE VEDRA, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- Analyst Upgrades
Truist Securities Reiterates Hold on Treace Medical Concepts, Lowers Price Target to $4
Truist Securities analyst Richard Newitter reiterates Treace Medical Concepts with a Hold and lowers the price target from $7 to $4. ...
- Analyst Upgrades
UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $5.85
UBS analyst Danielle Antalffy maintains Treace Medical Concepts with a Neutral and lowers the price target from $6.5 to $5.85. ...
- GlobeNewswire
Treace Announces Participation in Two Upcoming Investor Conferences
PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of ...
- Analyst Upgrades
JP Morgan Downgrades Treace Medical Concepts to Underweight, Lowers Price Target to $5
JP Morgan analyst Lilia-Celine Lozada downgrades Treace Medical Concepts from Neutral to Underweight and lowers the price target from $8 to $5. ...
- Analyst Upgrades
BTIG Downgrades Treace Medical Concepts to Neutral
BTIG analyst Ryan Zimmerman downgrades Treace Medical Concepts from Buy to Neutral. ...